Cargando…

An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study

INTRODUCTION: Chimeric antigen receptor T (CAR-T) cells are effective in treating hematological malignancies. However, in patients receiving CAR-T therapy, data characterizing cardiac disorders are limited. METHODS: 126 patients with hematologic malignancies receiving CAR-T cell therapy were analyze...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Kunming, Yan, Zhiling, Cheng, Hai, Chen, Wei, Wang, Ying, Wang, Xue, Cao, Jiang, Zhang, Huanxin, Sang, Wei, Zhu, Feng, Sun, Haiying, Li, Depeng, Wu, Qingyun, Qiao, Jianlin, Fu, Chunling, Zeng, Lingyu, Li, Zhenyu, Zheng, Junnian, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237759/ https://www.ncbi.nlm.nih.gov/pubmed/34195092 http://dx.doi.org/10.3389/fonc.2021.691064

Ejemplares similares

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021)

Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
por: Lu, Yanyan, et al.
Publicado: (2023)

Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
por: Xia, Jieyun, et al.
Publicado: (2023)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

Advantages of digital PCR in the detection of low abundance BCR-ABL1 gene in patients with chronic myeloid leukemia
por: Yan, Zhiling, et al.
Publicado: (2019)

Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia
por: Hong, Fei, et al.
Publicado: (2021)

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
por: Zhang, Huanxin, et al.
Publicado: (2022)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

p47phox deficiency impairs platelet function and protects mice against arterial and venous thrombosis
por: Wang, Xiamin, et al.
Publicado: (2020)

TIRC7 inhibits Th1 cells by upregulating the expression of CTLA-4 and STAT3 in mice with acute graft-versus-host disease
por: Zhu, Feng, et al.
Publicado: (2020)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)

A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
por: Liu, Yang, et al.
Publicado: (2023)

An absence of platelet activation following thalidomide treatment in vitro or in vivo
por: Qiao, Jianlin, et al.
Publicado: (2017)

NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis
por: Qiao, Jianlin, et al.
Publicado: (2018)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Platycodin D inhibits platelet function and thrombus formation through inducing internalization of platelet glycoprotein receptors
por: Luo, Qi, et al.
Publicado: (2018)

PEDF promotes the repair of bone marrow endothelial cell injury and accelerates hematopoietic reconstruction after bone marrow transplantation
por: Ju, Wen, et al.
Publicado: (2020)

Macrophages ameliorate bone marrow inflammatory injury and promote hematopoiesis in mice following hematopoietic stem cell transplantation
por: Qiao, Jianlin, et al.
Publicado: (2018)

miR-302 cluster inhibits angiogenesis and growth of K562 leukemia cells by targeting VEGFA
por: Cao, Jiang, et al.
Publicado: (2019)

Salidroside inhibits platelet function and thrombus formation through AKT/GSK3β signaling pathway
por: Wei, Guangyu, et al.
Publicado: (2020)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
por: Wang, Xue, et al.
Publicado: (2022)

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
por: Chen, Wei, et al.
Publicado: (2021)

Busulfan and cyclosphamide induce liver inflammation through NLRP3 activation in mice after hematopoietic stem cell transplantation
por: Qiao, Jianlin, et al.
Publicado: (2015)

Sjögren's Syndrome Complicated by Myeloid/Natural Killer Cell Precursor Acute Leukemia: Case Report and Review of the Literature
por: Feng, Hao, et al.
Publicado: (2016)

Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice
por: Zhang, Qing, et al.
Publicado: (2016)

Validation of Housekeeping Genes as Reference for Reverse-Transcription-qPCR Analysis in Busulfan-Injured Microvascular Endothelial Cells
por: Ju, Wen, et al.
Publicado: (2018)

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection
por: Niu, Anna, et al.
Publicado: (2023)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Matrine Impairs Platelet Function and Thrombosis and Inhibits ROS Production
por: Zhang, Sixuan, et al.
Publicado: (2021)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia
por: Fu, Lin, et al.
Publicado: (2017)

CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells
por: Li, Guangchao, et al.
Publicado: (2021)

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
por: Zou, Yixin, et al.
Publicado: (2018)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Role of T cell immune response cDNA 7 on the pathology of acute graft-versus-host disease
por: Zhu, Feng, et al.
Publicado: (2020)

At S126
por: CERN PhotoLab
Publicado: (1974)

At S126
por: CERN PhotoLab
Publicado: (1974)

Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy
por: Mei, Heng, et al.
Publicado: (2022)

Chimeric antigen receptor engineered natural killer cells for cancer therapy
por: Zhang, Yalan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m92fuqtjnodc1s43u9208loom9